AstriVax

Committed to address
real-world challenges
in vaccinology

Discover AstriVax

AstriVax NV is a privately held Belgian company founded in 2022 based on vaccine technology developed at the Rega Institute (KU Leuven). AstriVax has secured a seed round of € 30 million with a strong investor syndicate to continue building the vaccine technology platform and bring the first vaccines into clinical development. The company is located in Haasrode (Leuven).

  • First in class Plug & Play vaccine platform.

  • Patented DNA-based technology that launches self-amplifying live attenuated viruses, resulting in polyfunctional and vigorous nature of the immune response.

  • Wide range of potential use – prophylactic and therapeutic vaccines.

Let’s talk

About

Committed to address real-world challenges in vaccinology

Learn more about us

Technology

Patented DNA based technology that launches self-amplifying live attenuated viruses

Discover our technology

Pipeline

Prophylactic and Therapeutic Vaccines

Get insight in the pipeline

News

Learn more about AstriVax

Check the latest news